respiratory syncytial virus (RSV)
GPTKB entity
Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:affects |
elderly
infants people with heart disease possible in severe cases people with chronic lung disease |
| gptkbp:caused_by |
respiratory infections
|
| gptkbp:characteristics |
enveloped virus
single-stranded RNA virus |
| gptkbp:clinical_trial |
ongoing for vaccines
ongoing for antiviral drugs |
| gptkbp:complications |
gptkb:healthcare_organization
hospitalization bronchiolitis |
| gptkbp:end_of_life |
higher in high-risk groups
low in healthy individuals |
| gptkbp:family |
gptkb:Paramyxoviridae
|
| gptkbp:genus |
gptkb:Pneumovirus
|
| gptkbp:grooming_needs |
up to 3 weeks
|
| gptkbp:healthcare |
gptkb:battle
significant during outbreaks |
| https://www.w3.org/2000/01/rdf-schema#label |
respiratory syncytial virus (RSV)
|
| gptkbp:incubation_period |
2 to 8 days
|
| gptkbp:is_popular_in |
common worldwide
|
| gptkbp:is_protected_by |
hand hygiene
avoiding close contact with infected individuals |
| gptkbp:is_recognized_by |
gptkb:1956
|
| gptkbp:is_vulnerable_to |
no widely available vaccine
|
| gptkbp:provides_information_on |
WHO recommendations
CDC recommendations |
| gptkbp:public_awareness |
important for prevention
|
| gptkbp:research_focus |
vaccine development
antiviral treatments immune response studies |
| gptkbp:risk_factor |
immunocompromised individuals
premature infants children under 2 years old |
| gptkbp:seasonal_activities |
winter months
|
| gptkbp:social_responsibility |
seasonal outbreaks
PCR test rapid antigen test nasal swab |
| gptkbp:symptoms |
cough
fever runny nose wheezing |
| gptkbp:transmission |
contaminated surfaces
person-to-person contact aerosolized droplets |
| gptkbp:treatment |
gptkb:ribavirin
supportive care monoclonal antibodies oxygen therapy |
| gptkbp:type_of |
A subtype
B subtype |
| gptkbp:bfsParent |
gptkb:Synagis
|
| gptkbp:bfsLayer |
5
|